U.S. markets closed
  • S&P 500

    4,513.04
    -53.96 (-1.18%)
     
  • Dow 30

    34,022.04
    -461.68 (-1.34%)
     
  • Nasdaq

    15,254.05
    -283.64 (-1.83%)
     
  • Russell 2000

    2,147.42
    -51.49 (-2.34%)
     
  • Crude Oil

    66.45
    +0.88 (+1.34%)
     
  • Gold

    1,782.10
    -2.20 (-0.12%)
     
  • Silver

    22.36
    +0.03 (+0.12%)
     
  • EUR/USD

    1.1320
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.4340
    -0.0090 (-0.62%)
     
  • GBP/USD

    1.3278
    +0.0001 (+0.01%)
     
  • USD/JPY

    112.9200
    +0.1400 (+0.12%)
     
  • BTC-USD

    56,967.40
    -259.63 (-0.45%)
     
  • CMC Crypto 200

    1,442.71
    -26.37 (-1.79%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,704.05
    -231.57 (-0.83%)
     

Insulet's Insulin Delivery System Shows Durable Glycemic Control With One Year of Use

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Insulet Corporation (NASDAQ: PODD) presented data from the pivotal trial extension phase of the Omnipod 5 Automated Insulin Delivery System.

  • Omnipod 5 is a tubeless, wearable system that continuously adapts insulin delivery based on glucose levels and trends.

  • Data showed Omnipod 5 significantly improved time in range and reduced HbA1c patients aged 6-70 years with type 1 diabetes over a period of 12 months.

  • The data was presented at EASD 2021, the annual meeting of the European Association for the Study of Diabetes.

  • After three months of system use, adults and adolescents had a decrease in HbA1c from 7.2% to 6.8%.

  • This decrease was maintained after a total of 12 months of use, with mean HbA1c remaining at 6.8%.

  • The Omnipod 5 System received breakthrough device designation from the FDA and is currently under premarket review.

  • Insulet expects to launch Omnipod 5 in limited release in the U.S. late in Q4 of 2021.

  • Insulet also presented new clinical outcomes data for people with type 1 diabetes using the Omnipod DASH System for 90 days and positive self-management behaviors.

  • Related: FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps.

  • Price Action: PODD stock is up 1.42% at $282.93 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.